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ABSTRACT
Background: Chronic cough is the only symptom of cough variant asthma (CVA) and atopic cough (AC). Cys-
teinyl leukotriene receptor antagonists have been shown to be effective in CVA, but there are no reports on
their effectiveness in AC. To evaluate the antitussive effect of montelukast, a leukotriene receptor antagonist, in
CVA and AC.
Methods: Seventy-five patients with chronic cough received diagnostic bronchodilator therapy with oral clen-
buterol hydrochloride for 6 days. Of the 75 patients, 48 and 27 met the simplified diagnostic criteria for CVA and
AC, respectively. Patients with CVA were randomly divided into 3 groups: montelukast, clenbuterol, and mon-
telukast plus clenbuterol. Patients with AC were randomly divided into 2 groups: montelukast and placebo. The
efficacy of cough treatment was assessed with a subjective cough symptom scale (0 meant “no cough” and 10
denoted “cough as bad as at first visit”). The cough scale, pulmonary function test, and peak expiratory flow
rate (PEF) were evaluated before and after 2 weeks of treatment.
Results: In patients with CVA, 2-week treatment with montelukast, clenbuterol, and montelukast plus clen-
buterol all significantly decreased cough scores and treatment with montelukast plus clenbuterol was superior
to treatment with montelukast alone. In the montelukast plus clenbuterol group, PEF values in the morning and
evening significantly increased after 2 weeks compared with values before treatment. In patients with AC,
scores on the cough scale did not differ significantly between the montelukast group and the placebo group.
Conclusions: Montelukast was confirmed to suppress chronic non-productive cough in CVA, whereas it was
not effective in non-productive cough in AC.
KEY WORDS
atopic cough, cough score, cough variant asthma, leukotriene receptor antagonist, montelukast
INTRODUCTION
Chronic cough is a common complaint for which pa-
tients seek medical attention from primary care phy-
sicians.1 In Japan, cough variant asthma (CVA),
atopic cough (AC), and sinobronchial syndrome are
the top 3 causes of chronic cough,2 in contrast to
post-nasal drip syndrome, gastro-esophageal reflux
disease, and CVA in the United States and the United
Kingdom.3,4
CVA was originally described by Glauser5 in 1972
and subsequently by Corrao et al.6 in 1979 who
showed that the cough was responsive to bronchodi-
lator therapy, implying that it was caused by bron-
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choconstriction. AC has been defined as an isolated
chronic cough resistant to bronchodilator therapy, no
variable airflow obstruction, normal airway respon-
siveness, increased cough reflex sensitivity, and one
or more objective indication of atopic constitution as
defined by blood or sputum eosinophilia, elevated to-
tal or specific immunoglobulin E (IgE) levels, or posi-
tive skin tests.7 Sinobronchial syndrome presenting
with productive cough manifests as chronic sinusitis
and chronic neutrophilic inflammation of the lower
airways, such as chronic bronchitis, diffuse bron-
chiectasis, and diffuse panbronchiolitis.8 As is usual
in classic asthma, CVA responds to treatment with in-
haled bronchodilators4 and inhaled or systemic corti-
costeroid therapy.9 AC is characteristically resistant
to treatment with bronchodilators but responds to
histamine H1 antagonists and inhaled corticosteroid
therapy.10
Cysteinyl leukotrienes (LTC4, LTD4, and LTE4)
play a major role in the pathogenesis of chronic in-
flammation in asthma. Selective CysLT1 (LTD4) re-
ceptor antagonists have been shown to improve clini-
cal symptoms and pulmonary function in classic
asthma.11 In a randomized, double-blind, placebo-
controlled pilot study in 14 patients with CVA, the
leukotriene receptor antagonist montelukast was as-
sociated with significant improvement in cough.12
However, the effectiveness of a cysteinyl leukotriene
receptor antagonist on cough in AC has not been re-
ported.
Montelukast is a potent and selective antagonist of
the cysteinyl leukotriene receptor. The aim of this
study was to evaluate the effect of montelukast on
cough and pulmonary function in patients with CVA
and AC.
METHODS
PATIENTS
Ninety-nine patients, whose sole or predominant res-
piratory symptom was chronic cough persisting for
more than 8 weeks but without wheezing or dyspnea,
were enrolled in this study. Participants were from 8
institutes associated with the Kanazawa Asthma Re-
search Group. Participants had no history of asthma.
Wheezes or rhonchi were not audible on chest aus-
cultation even at forced expiration. Eosinophil counts
in the peripheral blood and sputum, total and specific
serum IgE levels, chest and sinus X-ray, bronchial re-
versibility in terms of increase in forced expiratory
volume in 1 second (FEV1) by an inhaled β2 agonist,
salbutamol sulfate at a dose of 300 μg (SultanolTM,
GlaxoSmithKline, Tokyo, Japan; 100 μg per puff) was
examined at the first visit. Patients with other causes
of chronic cough, as determined by the investigators
based on the clinical history, physical examination,
chest and sinus X-ray, examination of total and spe-
cific serum IgE levels, sputum eosinophils, and diag-
nostic treatment procedures recommended by the
JRS guidelines8 were excluded. The study was ap-
proved by the ethics committee of each institute, and
written informed consent was obtained from all par-
ticipating patients.
STUDY PROTOCOL (Fig. 1)
After the diagnostic procedure including therapeutic
diagnosis, 48 and 27 patients were diagnosed to have
CVA and AC, respectively. Bronchodilator therapy
which all participating patients received was as fol-
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lows: oral clenbuterol hydrochloride (SpiropentTM,
Teijin Pharma, Tokyo, Japan; 10 μg per tablet, 2 tab-
lets twice daily, 40 μg per day) plus inhaled salbuta-
mol (200 μg, on demand) for 6 days until the day be-
fore the second visit (observation period). Efficacy of
bronchodilator therapy on cough was assessed as de-
scribed below, and bronchial responsiveness to meth-
acholine was measured at the second visit (1 week af-
ter the first visit). Patients with CVA were randomly
divided into 3 treatment groups: the montelukast
group (SingulairTM, Banyu, Tokyo, Japan; 10 mg per
tablet, 1 tablet once daily), clenbuterol group, and
montelukast plus clenbuterol group. Patients with AC
were randomly divided into 2 treatment groups: the
montelukast group and the placebo group. Randomi-
zation was performed by each physician based on the
patient’s chart number. Drugs were administrated to
patients with CVA or AC during 2 weeks from the
second visit (treatment period). Pulmonary function
was measured at the third visit (2 weeks after the sec-
ond visit). Peak expiratory flow rates (PEFs) in the
morning and in the evening were recorded on a
“cough diary” every day for 3 weeks (during the 1-
week observation period and the 2-week treatment
period). Patients recorded cough symptom scale
scores 4 times daily (morning, afternoon, evening,
and night) and PEF twice daily (morning and eve-
ning).
ASSESSMENT OF EFFICACY OF TREATMENT
ON COUGH
The efficacy of treatment on cough was assessed with
a subjective cough symptom scale (cough scale).
During the 1-week observation period and the follow-
ing 2-week treatment period, all patients recorded
their cough scores in a cough diary. Cough was
scored on a scale from 0 to 10 points, based on the se-
verity and frequency of their cough for 24 hours at
the first visit, after the 1-week observation period, and
after the 2-week treatment period. A score of 0 meant
“no cough,” whereas a score of 10 denoted “cough as
bad as at first visit.”13 Based on the diaries, the aver-
age of three days (days 5, 6, and 7 from the first visit)
was used as the cough scale score for week 1 and
that of three days (days 19, 20 and 21 from the first
visit) was used as the cough scale score for week 3.
The efficacy of bronchodilator therapy to make a
diagnosis of CVA was evaluated on the basis of the
change in the cough scale score before and after
treatment (∆ cough scale): 10-8 points was regarded
as excellent, 7-5 points as good, 4-3 points as fairly
good and 2-0 points as unsatisfactory. When ∆ cough
scale was 3 or more, bronchodilator therapy was
judged to be effective.
DIAGNOSIS OF CVA AND AC
CVA and AC as sole causes of chronic cough were di-
agnosed according to the simplified diagnostic crite-
ria recommended by the Japanese Respiratory Soci-
ety (JRS).8 The diagnosis of CVA was made accord-
ing to the following criteria: (1) isolated chronic non-
productive cough lasting more than 8 weeks; (2) ab-
sence of a history of wheezing or dyspnea, and no ad-
ventitious lung sounds on physical examination; (3)
relief of cough with bronchodilator therapy; and (4)
FEV1, forced vital capacity (FVC), and FEV1FVC ra-
tio within normal limits. The diagnosis of AC was
made according to the following criteria8: (1) non-
productive cough lasting more than 8 weeks without
wheezing or dyspnea; (2) cough resistant to bron-
chodilator therapy (oral clenbuterol 40 μgday plus
inhaled salbutamol 200 μg at bedtime and on de-
mand); (3) presence of one or more findings indica-
tive of an atopic constitution, including a history and
or complications of allergic disease excluding
asthma, peripheral blood eosinophilia (>5% or >400
cellsμL), elevated total serum IgE level (>150 IU
mL), positive specific IgE antibody to aeroallergens
andor induced sputum eosinophilia (2.5%); (4)
resolution of cough attack with histamine H1 antago-
nists andor inhaled andor oral corticosteroid ther-
apy.
PULMONARY FUNCTION TESTING
Routine pulmonary function was measured at the first
visit, the second visit (1 week after the first visit), and
the third visit (2 weeks after the second visit). Bron-
chial reversibility was measured at the first visit, and
bronchial responsiveness was determined at the sec-
ond visit. FVC and FEV1 were measured using a dry
wedge spirometer (Chestac 11, Chest, Tokyo, Japan).
Spirometry was performed and evaluated according
to the American Thoracic Society criteria.14 To assess
bronchial reversibility, spirometry was performed be-
fore and 30 minutes after inhalation of 300 μg salbuta-
mol sulfate. PC20, the provocative concentration of
methacholine solution causing a 20% fall in FEV1
from the baseline value, was measured as an index of
non-specific bronchial responsiveness.15
STATISTICAL ANALYSIS
Data values for PC20 were expressed as geometric
mean with geometric standard error of the mean
(GSEM). Other data values were expressed as mean
and SD. The Wilcoxon signed rank test (paired sign
test) was used for within-group analyses, and the
Mann-Whitney U test was used for comparisons be-
tween CVA and AC, and between-group analyses.
Data for PC20 were logarithmically transformed. P-
values <0.05 were considered statistically significant.
RESULTS
PATIENT CHARACTERISTICS
Diagnostic procedures were completed in 75 of 99 pa-
tients with chronic cough who were enrolled in this
study. Of the 75 patients, 48 and 27 patients, respec-
Kita T et al.
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Table 1 Patient characteristics
ACCVA
TotalMontelukastControlTotalClenbuterol+ montelukastMontelukastClenbuterol
2719848191316Number of subjects
45.3 ± 16.847.2 ± 17.440.9 ± 15.448.8 ± 17.148.9 ± 17.143.3 ± 18.253.1 ± 15.7Age (yr)
 9/18 7/122/621/27 9/106/7 6/10Male/female
 7/20 6/131/715/33 6/135/8 4/12Smoking states (+/-)
38.3 ± 77.337.2 ± 74.040.5 ± 88.731.8 ± 57.331.4 ± 59.728.5 ± 42.835.1 ± 67.1Cough duration(weeks)
160.5 ± 98.0 158.5 ± 98.7 165.1 ± 102.9202.4 ± 151.2223.1 ± 201.1176.6 ± 135.7200.2 ± 91.8 Eosinophils (/μL)
114.5 ± 149.1 91.5 ± 130.3173.7 ± 187.6233.1 ± 549.1268.8 ± 757.3120.5 ± 142.4287.8 ± 454.2Total IgE (IU/mL)
105.9 ± 21.4 103.3 ± 21.2 112.4 ± 21.6 108.0 ± 14.6 105.9 ± 18.3 109.4 ± 12.3 109.2 ± 11.5 FVC, % predicted
104.9 ± 16.0 103.3 ± 15.8 108.5 ± 16.9 100.0 ± 20.0 100.4 ± 15.5 97.1 ± 32.5101.8 ± 10.4 FEV1, % predicted
83.4 ± 8.0 83.0 ± 8.8 84.3 ± 6.1 80.5 ± 9.9 81.8 ± 11.282.2 ± 7.4 77.7 ± 9.9 FEV1/FVC (%)
16.2 (3.56)14.6 (4.00)21.5 (2.70)10.89 (6.34)8.36 (9.90)20.9 (3.80)7.66 (6.10)PC20 (mg/mL)
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; PC20, provocative concentration of methacholine causing a 
20% fal in FEV1. Data are expressed as mean (SD) except PC20 which is expressed as geometric mean (GSEM) values.
Fig. 2 Changes in scores of the cough scale in patients 
with CVA. Filed squares indicate the change in cough scale 
score in patients treated with montelukast (n = 13). Filed tri-
angles indicate the change in the cough scale score in pa-
tients treated with clenbuterol (n = 16). Filed circles indicate 
the change in the cough scale score in patients treated with 
clenbuterol plus montelukast (n = 19) . Data are expressed 
as the mean (SD). Scores on the cough scale in the clen-
buterol group (***p < 0.05), montelukast group (**p < 0.01), 
and clenbuterol plus montelukast group (**p < 0.01) were 
significantly decreased at week 3 compared with week 1 
(Wilcoxon signed rank test). Scores in the clenbuterol plus 
montelukast group decreased significantly more than scores 
in the montelukast group (*p < 0.05, Mann-Whitney U test).
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Fig. 3 Changes in scores of the cough scale in patients 
with atopic cough (AC). Filed triangles indicate the change 
in cough scale score in patients treated with placebo (n = 8). 
Filed squares indicate the change in cough scale score in 
patients treated with montelukast (n = 19). Data are ex
pressed as the mean (SD). Scores on the cough scale in the 
montelukast group (*p < 0.05) was significantly decreased 
at week 3 compared with week 1 (Wilcoxon signed rank 
test). Scores on the cough scale at week 3 were not signifi
cantly diferent between the placebo and montelukast 
groups.
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tively, met the simplified diagnostic criteria for CVA
and AC as the sole causes of chronic cough. Eight pa-
tients with sinobronchial syndrome, 6 with post-
infectious disorders, 4 with gastro-esophageal reflux
disease, 2 with psychogenic cough, and 4 with
Montelukast is Useful for Cough Symptoms
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Fig. 4 Changes in morning peak flow rate (PEF) for treat
ment with montelukast (filed squares) , clenbuterol (filed tri
angles) , and clenbuterol plus montelukast (filed circles) in 
patients with CVA. Data are expressed as the mean (SD) . 
In the montelukast plus clenbuterol group, PEF values in the 
morning at week 3 were increased significantly (p < 0.05) 
compared with values at week 1.
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Fig. 5 Changes in evening peak flow rate (PEF) for treat
ment with montelukast (filed squares), clenbuterol (filed tri
angles), and clenbuterol plus montelukast (filed circles) in 
patients with CVA. Data are expressed as the mean (SD). In 
the montelukast plus clenbuterol group, PEF values in the 
evening at week 3 were increased significantly (p < 0.05) 
compared with values at week 1.
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chronic cough of unknown etiology were excluded
from this study. Patient characteristics are summa-
rized in the Table 1.
COUGH SYMPTOMS
In the CVA groups (montelukast, clenbuterol, and
montelukast plus clenbuterol), scores on the cough
scale at week 1 were decreased significantly (5.2 ±
2.5, 3.0 ± 1.4, 4.2 ± 1.8, respectively) compared with
the baseline (week 0), and the scores at week 3 were
further decreased significantly (2.7 ± 2.4, 2.1 ± 1.8,
1.3 ± 1.0, respectively) in comparison with each value
at week 1 (Fig. 2). Scores on the cough scale in the
montelukast plus clenbuterol group were signifi-
cantly decreased compared with scores in the mon-
telukast group (Fig. 2). In the AC groups (montelu-
kast and placebo), scores on the cough scale at week
1 did not significantly differ from the baseline scores
(Fig. 3). In the montelukast group, scores on the
cough scale at week 3 (8.0 ± 2.3) were decreased sig-
nificantly compared with scores at week 1 (9.6 ± 0.8)
(Fig. 3), whereas in the placebo group, scores on the
cough scale did not differ between week 1 and week
3 (Fig. 3). However, scores on the cough scale with
montelukast and placebo at week 1 or week 3 were
not significantly different (Fig. 3), suggesting no sig-
nificant effect of montelukast on the cough in AC.
PEAK EXPIRATORY FLOW RATE (PEF) AND
PULMONARY FUNCTION
In the montelukast plus clenbuterol group with CVA,
PEF values in the morning and evening at week 3
(433.5 ± 155.0 and 446.9 ± 157.3 Lmin, respectively)
were increased significantly (p < 0.05) compared with
values at week 1 (400.3 ± 152.3 and 433.5 ± 155.0 L
min, respectively). In the montelukast group and
clenbuterol group with CVA, morning and evening
PEF values were not different between week 1 and
week 3 (Fig. 4, 5). In the montelukast group and pla-
cebo group with AC, PEF values in the morning and
evening were not different between week 1 and week
3 (Fig. 6, 7). FVC and FEV1 did not significantly
change from week 0 to week 1 or week 3 in the 3
groups with CVA and 2 groups with AC (data not
shown).
DISCUSSION
This is the first, randomized, prospective study that
showed the ineffectiveness of the CysLT1 receptor
antagonist montelukast in patients with AC. The pre-
sent study also confirmed the effectiveness of mon-
telukast but could not show the significant additive ef-
fect of montelukast plus bronchodilator treatment in
the patients with CVA.
CVA was originally described by Glauser5 in 1972
and subsequently by Corrao et al.6 The only present-
ing symptom of CVA is isolated chronic cough re-
sponsive to bronchodilator treatment. Recognition of
Kita T et al.
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Fig. 6 Changes in morning peak flow rate (PEF) with treat
ment with montelukast (filed squares) and placebo (filed tri
angles) in patients with AC. Data are expressed as the 
mean (SD).
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Fig. 7 Changes in evening peak flow rate (PEF) with treat
ment with montelukast (filed squares) and placebo (filed tri
angles) in patients with AC. Data are expressed as the 
mean (SD).
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CVA is clinically important because bronchodilator
treatment is only effective in CVA. Bronchodilators
usually exert no antitussive effect in other causes of
isolated chronic cough.16 Niimi et al.17 reported that
eosinophilic airway inflammation is present by docu-
menting the increased number of eosinophils in bron-
choalveolar lavage fluid and biopsied bronchial mu-
cosa and subepithelial-layer thickness occurs in CVA
as well as classic asthma.18,19 Kim et al. reported that
sputum eosinophilia is associated with subsequent
development of classic asthma, and that children with
CVA who developed wheezing demonstrated a fur-
ther increase in airway responsiveness to meth-
acholine.19,20 Nearly 30% of CVA patients eventually
develop wheezing, sometimes severe enough to re-
quire continuous treatment with bronchodila-
tors.6,21,22 We previously showed that long-term in-
haled corticosteroid therapy could prevent typical
asthma onset from CVA, and that bronchial hyperre-
sponsiveness was the most important risk factor for
typical asthma onset from CVA.23
AC is characterized by an atopic background, spu-
tum eosinophilia, cough reflex hypersensitivity, nor-
mal pulmonary function, and normal bronchial re-
sponsiveness. Cough responds to histamine H1 an-
tagonists24 and corticosteroids, but not to bronchodi-
lators. Eosinophilic inflammation occurs in central,
but not peripheral, airways,10 and is more prominent
in more severe disease.25 Eosinophilic bronchitis
without asthma was first described by Gibson et al.26
AC shares several features with eosinophilic bronchi-
tis, but may differ by the lack of bronchoalveolar lav-
age eosinophilia,10,25 no increased levels of exhaled
nitric oxide,27 and no transformation to typical
asthma.7 Bronchoalveolar lavage eosinophilia,28,29 in-
creased exhaled nitric oxide,29,30 and transformation
to typical asthma31 have been shown in eosinophilic
bronchitis.
In this study, in patients with CVA, scores on the
cough scale decreased after 2 weeks of treatment
with montelukast and clenbuterol equally, and scores
decreased significantly more with montelukast plus
clenbuterol as compared with montelukast alone, but
not as compared with clenbuterol alone. The present
study failed to show an additive effect of montelukast
on bronchodilator therapy in the patients with CVA.
The following issues are likely to be responsible for
the negative results. The cough symptom was too im-
proved with the 6-day bronchodilator treatment to
evaluate the superior efficacy of montelukast plus
clenbuterol beyond montelukast or clenbuterol alone.
In addition, in the clenbuterol group, scores in the
cough scale at week 1 of treatment with clenbuterol
were too low to compare with other groups (montelu-
kast alone and montelukast plus clenbuterol). Future
study using other protocols is required to elucidate
the additive efficacy of montelukast with clenbuterol
in CVA. On the other hand, in patients with AC,
scores in the cough scale did not differ significantly
between the montelukast group and the placebo
group.
Dicpinigaitis et al.13 reported that a 14-day treat-
ment with zafirlukast demonstrated significant im-
provement in cough in 7 of 8 patients with CVA. Spec-
tor et al.12 reported that mean percentage change
from baseline in cough frequency was significantly
improved by the second week, and the mean percent-
age change at the fourth week from baseline was
75.7% for the montelukast group and 20.7% for the pla-
cebo group in patients with CVA. These reports are
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consistent with the results of our study, demonstrat-
ing a significant decrease in scores in the cough
scales in the montelukast group.
We planned this study design to confirm the effi-
cacy of montelukast in CVA and used the positive
control treatment in this study, because several re-
ports have shown the efficacy of leukotriene antago-
nists for CVA.12,13 Thus, we could not evaluate the
carry-over effect of clenbuterol in this study. This is-
sue should be evaluated in future studies. Another
objective of this study was to examine the efficacy of
leukotriene antagonists for AC because the effect of
leukotriene antagonists for AC has not been evalu-
ated. In other words, this trial is the first one to eluci-
date it. Accordingly, we employed the negative pla-
cebo treatment group to elucidate the efficacy of
montelukast for AC. The reasons why we did not use
histamine H1-antagonists as a positive treatment for
AC are as follows: 1) the diagnosis of atopic cough
was made mainly based on therapeutic diagnostic
procedures recommended by the JRS guidelines.
Thus, patients with chronic cough, whose cough did
not respond to the 6-day bronchodilator therapy,
were suspected to have AC and received the test
treatment of AC. After this, individual patients were
treated according to the JRS guidelines and AC was
diagnosed when the cough was completely relieved
by histamine H1 antagonists andor inhaled andor
oral corticosteroids and: 2) we expected that leukot-
riene antagonists were not effective for AC based on
our previous findings using an animal model of AC in
which montelukast failed to reduce the increased
cough response to inhaled capsaicin 24 hours after
antigen challenge in actively sensitized guinea pigs.32
So, negative control treatment was necessary instead
of positive control treatment with histamine H1-
antagonists to elucidate the efficacy of montelukast
for AC.
Birring et al.33 measured inflammatory mediator
concentrations in induced sputum supernatant from
18 controls and 62 patients with various types of
chronic cough, including 20 patients with CVA.
Prostaglandin D2 and prostaglandin E2 levels were
significantly higher in all the cough groups compared
with controls, whereas LTC4, LTD4, and LTE4 levels
were significantly higher only in CVA and eosino-
philic bronchitis compared with controls. Inhibition
of elevated levels of LTC4, LTD4, and LTE4 in pa-
tients with CVA and eosinophilic bronchitis by mon-
telukast would be the potential mechanism for the
beneficial effects of montelukast.
Our previous study showed that there was a small
but significant increase in FEV1 following successful
treatment in CVA.34 Thus, it is likely that a small de-
gree of airway smooth muscle contraction triggers
cough in CVA. Reiss et al.35 demonstrated the ability
of montelukast to cause bronchodilatation in asth-
matic subjects with baseline airflow limitation. In this
study, both morning and evening PEF were in-
creased after treatment with montelukast and clen-
buterol in patients with CVA, but not in patients with
AC. This finding suggests that the effect of montelu-
kast on cough might result from relief of cysteinyl
leukotrienes-mediated smooth muscle contraction in
patients with CVA.
In this study, geometric mean values for PC20
were not significantly different between the three
groups in patients with CVA. In addition, it has been
shown that measurement of PC20 could not predict
the efficacy of bronchodilator therapy in patients with
chronic cough,36 and we and other research groups
have confirmed the uselessness of PC20 measure-
ment for diagnosis of cough variant asthma. To our
knowledge, no reports are available concerning the
relationship between severity of cough variant
asthma and bronchial hyperresponsiveness. The defi-
nition of illness severity for cough variant asthma has
not been established. Severity of illness should be
graded in the future. In each case, it should be deter-
mined which intensity and frequency of coughing or
difficulty of treatment is important.
One limitation of our study was that we did not aim
to determine the mechanism behind the effects of
montelukast in cough. Montelukast has the potential
to prevent the release of arachidonic acid and bron-
choconstriction induced by inflammatory mediators.
The anti-inflammatory effect of montelukast is not
stronger than that of inhaled corticosteroids, and its
bronchodilator effect is not stronger than β2 ago-
nists.37,38 In this study, scores on the cough scale
with montelukast were not significantly different from
scores with placebo in patients with AC, which is con-
sistent with our previous findings using an animal
model of AC.32 These findings suggest that leukot-
riene receptor antagonists have no benefit in the
treatment of AC.
In conclusion, montelukast was confirmed to sup-
press chronic non-productive cough in patients with
CVA and the effect of suppression was equal to clen-
buterol. However, montelukast was not effective in
patients with AC, strongly suggesting that cysteinyl
leukotrienes are not involved in the pathogenesis of
AC. Future studies are required to confirm the bene-
ficial effect of montelukast in the treatment of CVA
and to clarify the mechanism of its antitussive action.
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